Literature DB >> 15531316

Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.

Laurence Postelmans1, Brigitte Pasteels, Pascale Coquelet, Hind El Ouardighi, Claire Verougstraete, Ursula Schmidt-Erfurth.   

Abstract

PURPOSE: Although photodynamic therapy (PDT) is an established treatment for choroidal neovascularization (CNV), the mechanisms are still not completely elucidated. Damage to the retinal pigment epithelium (RPE) was observed following uncomplicated PDT in young patients.
DESIGN: Observational case series.
METHODS: Four female patients between the age of 26 and 39 years presented with visual loss because of classic CNV. In two 39 years old females the CNV originated secondary to a small chorioretinal scar, in a 26 and a 36-year-old woman the CNV was of idiopathic cause. All patients received standard PDT according to the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study protocol.
RESULTS: One to three months after an uncomplicated PDT with verteporfin, severe pigment epithelial alterations in the treatment area were observed. The neovascular membranes responded favorably to the treatment and demonstrated fibrosis and resolution of leakage. Ophthalmoscopically and angiographically, atrophy of the retinal pigment epithelium was seen precisely delineating the size of the treatment spot used. Vision declined in two patients from 0.3 to 0.1 and 0.15 to 0.1. The two other patients demonstrated an increase of visual acuity from 0.7 to 0.9 and from 0.4 to 0.9. The retinal pigment epithelium alterations did not resolve during follow-up, but remained unchanged in area and intensity.
CONCLUSIONS: Characteristic retinal pigment epithelium alterations were observed in young female patients with small classic CNV following PDT. Unusual retinal pigment epithelium damage in young female patients without any associated disease might be related to a possible inherent defect in the RPE or to the hormonal status of this specific patient population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531316     DOI: 10.1016/j.ajo.2004.06.033

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  25 in total

1.  The effect of digital measurement software on photodynamic therapy.

Authors:  Siamak Ansari-Shahrezaei; Erdem Ergun; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-17       Impact factor: 3.117

2.  Photodynamic treatment versus photodynamic treatment associated with systemic steroids for idiopathic choroidal neovascularisation.

Authors:  Alfonso Giovannini; Piergiorgio Neri; Lucia Mercanti; Claudia Bruè
Journal:  Br J Ophthalmol       Date:  2007-01-03       Impact factor: 4.638

3.  Treatment frequency and visual outcome in subfoveal choroidal neovascularization related to pathologic myopia treated with photodynamic therapy.

Authors:  Noémi Maár; Erdem Ergun; Alexandra Luksch; Michael Stur
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

4.  Pigment epithelial changes with abnormal fundus autofluorescence after photodynamic therapy for idiopathic choroidal neovascularization.

Authors:  Taku Wakabayashi; Fumi Gomi; Miki Sawa; Kunihiko Shiraki; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2008-04-30       Impact factor: 2.447

5.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

Authors:  R Obata; A Iriyama; Y Inoue; H Takahashi; Y Tamaki; Y Yanagi
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

6.  Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization.

Authors:  José M Ruiz-Moreno; Javier A Montero; Pedro Amat; Francisco Lugo
Journal:  Int J Ophthalmol       Date:  2010-06-18       Impact factor: 1.779

7.  Effect of photodynamic therapy on the function of the outer blood-retinal barrier in an in vitro model.

Authors:  Stefan Mennel; Silvia Peter; Carsten H Meyer; Gabriele Thumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-19       Impact factor: 3.117

8.  Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.

Authors:  Markus S Ladewig; Stefanie E Karl; Victoria Hamelmann; Hans-Martin Helb; Hendrik P N Scholl; Frank G Holz; Nicole Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-15       Impact factor: 3.117

Review 9.  Stem cells as tools in regenerative therapy for retinal degeneration.

Authors:  Volker Enzmann; Esma Yolcu; Henry J Kaplan; Suzanne T Ildstad
Journal:  Arch Ophthalmol       Date:  2009-04

10.  Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane.

Authors:  Mahesh P Shanmugam; H M Mythri; Nitin S Shetty
Journal:  Indian J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.